Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Anal cancer (squamous cell carcinoma), drawn from the whole corpus: 10 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
1 medicines on record are linked to one of the types below rather than to Anal cancer (squamous cell carcinoma) itself. Grouped by the type that holds them; each list opens that type's own page.
Screening programmes for high-risk groups exist almost nowhere despite ANCHOR.
Nothing recorded yet.
Also on OnCo: Symptoms and red flags · Early detection roadmap.
Late toxicity of pelvic chemoradiation (bowel, sexual, bone).
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Checkpoint side effects by organ · Side effect rates across a drug class · Survivorship planner.
HPV-negative anal cancer does poorly.
Stigma and delayed diagnosis.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 21 changes by month →When this page itself was last checked or edited.
FDA approved pembrolizumab (Keytruda, Merck) for adults with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin after surgery, and then as a single agent.
FDA approved retifanlimab-dlwr (Zynyz, Incyte Corporation) with carboplatin and paclitaxel for the first-line treatment of adults with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC).
Locally recurrent or metastatic anal SCC with carboplatin-paclitaxel; monotherapy after platinum
Median progression-free survival 9.
FDA approval 2025.